Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis

Abstract The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a meta-analysis to assess the risk of both pancreatic cancer and acute pancreatitis associat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lana C. Pinto, Dimitris V. Rados, Sabrina S. Barkan, Cristiane B. Leitão, Jorge L. Gross
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/81b767a656f546529e3bc567694357bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81b767a656f546529e3bc567694357bf
record_format	dspace
spelling	oai:doaj.org-article:81b767a656f546529e3bc567694357bf2021-12-02T15:08:19ZDipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis10.1038/s41598-017-19055-62045-2322https://doaj.org/article/81b767a656f546529e3bc567694357bf2018-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-19055-6https://doaj.org/toc/2045-2322Abstract The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a meta-analysis to assess the risk of both pancreatic cancer and acute pancreatitis associated with the use of DPP-4 inhibitors. We also used trial sequential analysis to evaluate whether the number of patients included was enough to reach conclusions. We included randomised controlled trials lasting 24 weeks or more that compared DPP-4 inhibitors with placebo or other antihyperglycaemic agents. A total of 59,404 patients were included. There was no relationship between the use of DPP-4 inhibitors and pancreatic cancer (Peto odds ratio 0.65; 95% CI 0.35–1.21), and the optimal sample size was reached to determine a number needed to harm (NNH) of 1000 patients. DPP-4 inhibitors were associated with increased risk for acute pancreatitis (Peto odds ratio 1.72; 95% CI 1.18–2.53), with an NNH of 1066 patients, but the optimal sample size for this outcome was not reached. In conclusion, there is no association between DPP-4 inhibitors and pancreatic cancer, and a small risk for acute pancreatitis was observed with DPP-4 inhibitor use, although the latter finding is not definitive.Lana C. PintoDimitris V. RadosSabrina S. BarkanCristiane B. LeitãoJorge L. GrossNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-6 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lana C. Pinto Dimitris V. Rados Sabrina S. Barkan Cristiane B. Leitão Jorge L. Gross Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
description	Abstract The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a meta-analysis to assess the risk of both pancreatic cancer and acute pancreatitis associated with the use of DPP-4 inhibitors. We also used trial sequential analysis to evaluate whether the number of patients included was enough to reach conclusions. We included randomised controlled trials lasting 24 weeks or more that compared DPP-4 inhibitors with placebo or other antihyperglycaemic agents. A total of 59,404 patients were included. There was no relationship between the use of DPP-4 inhibitors and pancreatic cancer (Peto odds ratio 0.65; 95% CI 0.35–1.21), and the optimal sample size was reached to determine a number needed to harm (NNH) of 1000 patients. DPP-4 inhibitors were associated with increased risk for acute pancreatitis (Peto odds ratio 1.72; 95% CI 1.18–2.53), with an NNH of 1066 patients, but the optimal sample size for this outcome was not reached. In conclusion, there is no association between DPP-4 inhibitors and pancreatic cancer, and a small risk for acute pancreatitis was observed with DPP-4 inhibitor use, although the latter finding is not definitive.
format	article
author	Lana C. Pinto Dimitris V. Rados Sabrina S. Barkan Cristiane B. Leitão Jorge L. Gross
author_facet	Lana C. Pinto Dimitris V. Rados Sabrina S. Barkan Cristiane B. Leitão Jorge L. Gross
author_sort	Lana C. Pinto
title	Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
title_short	Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
title_full	Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
title_fullStr	Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
title_full_unstemmed	Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
title_sort	dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/81b767a656f546529e3bc567694357bf
work_keys_str_mv	AT lanacpinto dipeptidylpeptidase4inhibitorspancreaticcancerandacutepancreatitisametaanalysiswithtrialsequentialanalysis AT dimitrisvrados dipeptidylpeptidase4inhibitorspancreaticcancerandacutepancreatitisametaanalysiswithtrialsequentialanalysis AT sabrinasbarkan dipeptidylpeptidase4inhibitorspancreaticcancerandacutepancreatitisametaanalysiswithtrialsequentialanalysis AT cristianebleitao dipeptidylpeptidase4inhibitorspancreaticcancerandacutepancreatitisametaanalysiswithtrialsequentialanalysis AT jorgelgross dipeptidylpeptidase4inhibitorspancreaticcancerandacutepancreatitisametaanalysiswithtrialsequentialanalysis
_version_	1718388197484920832

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis

Ejemplares similares